Randomized phase III study of gemcitabine versus TS-1 [S-1] versus gemcitabine plus TS-1 in unresectable advanced pancreatic cancer (with local progression or metastasis).
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms GEST
- Sponsors Taiho Pharmaceutical; TTY Biopharm
- 29 Dec 2015 Results (subgroup analysis) published in the European Journal of Cancer (n = 261).
- 18 Jan 2014 Pooled results for prognostic factors from GEST, GEMSAP, and JACCRO PC-01 presented at the 2014 Gastrointestinal Cancers Symposium.
- 03 Apr 2013 Results have been published in the online version of the Journal of Clinical Oncology according to a Taiho Pharmaceutical media release. Results were also summarised in the media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History